# Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults

> **NCT03382405** · PHASE1 · COMPLETED · sponsor: **ModernaTX, Inc.** · enrollment: 181 (actual)

## Conditions studied

- Cytomegalovirus Infection

## Interventions

- **BIOLOGICAL:** mRNA-1647
- **BIOLOGICAL:** mRNA-1443
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03382405
- **Lead sponsor:** ModernaTX, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-13
- **Primary completion:** 2020-10-28
- **Final completion:** 2020-10-28
- **Target enrollment:** 181 (ACTUAL)
- **Last updated:** 2021-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03382405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03382405, "Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03382405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*